Personalized CHF treatment: PCT to guide therapy in heart failure patients

Sorting out the etiology of dyspnea in patients with a history of heart failure is not always straightforward. Although an acute heart failure exacerbation would seem to be easy to distinguish from an acute respiratory illness, data from objective clinical studies has shown otherwise. Procalcitonin (PCT), a biomarker that rises in the setting of bacterial infection, carries great potential for guiding the diagnosis and treatment of heart failure patients with possible acute respiratory infection. In this issue of the International Journal of Cardiology, Kutz et al. demonstrated that patients with a history of heart failure and suspected lower respiratory tract infection experienced reduced antibiotic duration and superior outcomes with PCT-guided therapy. The results in this subset of heart failure patients from the ProHOSP study were consistent with the results seen in the overall study population. This study points to the need for a randomized controlled trial in a broader population of heart failure patients with acute dyspnea, to further define the prominent role that PCT can play in more personalized medical treatments that can improve patient outcomes.